New combo therapy aims to stop rare HER2-positive salivary gland cancer in its tracks
NCT ID NCT04620187
First seen Feb 28, 2026 · Last updated Jun 13, 2026 · Updated 22 times
Summary
This study tests whether adding the targeted drug T-DM1 to standard chemoradiation can prevent HER2-positive salivary gland cancer from returning after surgery. About 37 adults with advanced but removable tumors will receive the drug alongside standard care. Researchers will track cancer recurrence over two years and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 GENE MUTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Basking Ridge
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Bergen
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Commack
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Monmouth
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Nassau
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
Contact
-
Memorial Sloan Kettering Westchester
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
Contact
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Washington Medical Center
RECRUITINGSeattle, Washington, 98195, United States
Contact
Contact
-
Winship Cancer Institute, Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.